Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

BACKGROUND: Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment. METHODS: Patients with unresectable liver-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678276/
https://www.ncbi.nlm.nih.gov/pubmed/19386096
http://dx.doi.org/10.1186/1471-2407-9-120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678276/
https://www.ncbi.nlm.nih.gov/pubmed/19386096
http://dx.doi.org/10.1186/1471-2407-9-120

Ejemplares similares